Figure 2.

Mechanism of action of novel medications for AD. Monoclonal antibodies have large molecular weight and complex structure, which entails their extracellular function. They are characterized by highly specific inhibition of single interleukins or interleukin receptors. Small molecules act as intracellular kinase inhibitors, which limits downstream transduction of pro-inflammatory signals and subsequent transcription of a wide range of interleukins aggravating AD.